Catalyst
Slingshot members are tracking this event:
FDA Decision Expected By April 5th for Merck's (MRK) Glargine (MK-1293) in Type 1 and Type 2 Diabetes
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 20, 2017
Occurred Source:
http://www.mrknewsroom.com/news-release/research-and-development-news/merck-announces-us-fda-grants-tentative-approval-lusduna-
Related Projects
Related Keywords
Glargine, Mk-1293, Type 1 Diabetes, Type 2 Diabetes, Fda, Pdufa
